Syndax Pharmaceuticals (SNDX) said Tuesday the US Food and Drug Administration has granted priority review for its supplemental new drug application for Revuforj to treat relapsed or refractory mutant NPM1 acute myeloid leukemia.
The supplemental new drug application is being reviewed under the regulator's real-time oncology review program and has been assigned a prescription drug user fee act, or PDUFA, target action date of Oct. 25, the company said.
The company's shares were rising 1.2% in recent after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.